Lenz & Staehelin advised Climeworks through closing of its financing round, which raised equity of USD 162 million and represented the largest carbon removal investment of 2025 to date globally. BigPoint Holding and Partners Group led the
Tags :Beat Kühni
Vail Resort, advised by Lenz & Staehelin (L&S), has aquired an 84-percent ownership stake in Remontées Mécaniques Crans Montana Aminona, which controls and operates the Crans-Montana Mountain Resort in Switzerland, from
Beiersdorf AG, the German listed parent behind the luxury brand La Prairie, signed an agreement to acquire the real estate assets of Clinique La Prairie in Montreux, Switzerland. The real estate assets comprise several compounds
Vail Resorts has revealed plans to acquire an 84% ownership stake in Remontées Mécaniques Crans Montana Aminona (CMA), the entity managing the renowned Crans-Montana Mountain Resort in Switzerland. This acquisition includes an 80% ownership share
Lenz & Staehelin acted as legal advisors for Elos Medtech, a development and manufacturing partner for medical devices, on its recent expansion through its agreement to acquire Klingel Holding. The acquisition is valued at EUR 370
Union Investment, the international real estate company with headquarters in Hamburg, has closed the sale of its multi-tenant property «Westpark» located in Zurich-West to PSP Real Estate, a subsidiary of PSP Swiss Property, for CHF 216.5
Relai, a Switzerland-based Bitcoin-only investment platform, announced the closing of a USD 4.5 million financing. The round was led by ego death capital (EDC), with further participation from Timechain, Cabrit Capital and Lightning Ventures, as well
True Ventures has made a substantial investment in Exnaton, a Swiss startup developing a billing platform for renewable energies that enables the sharing of surplus solar power within a neighborhood. True Ventures is a Silicon
Last June 2022, Lubana, a renowned real estate manager and service provider in Switzerland, secured an equity investment from a new cooperation and investment partner representing a stake of more than 7% in the company. LUBANA, with
ImmunOs Therapeutics has closed an oversubscribed Series B financing round totaling USD 74 million. The round was led by new investors Samsara BioCapital, Lightspeed Venture Partners, and Gimv, and joined by new investors Mission BioCapital, GL
